Emergent BioSolutions has agreed to acquire GlaxoSmithKline’s (GSK) anthrax monoclonal antibody, raxibacumab, for around $96m.
Raxibacumab is a fully human monoclonal antibody, which secured approval from the US Food and Drug Administration (FDA) for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis.
{iframe}http://www.pharmaceutical-business-review.com/news/emergent-biosolutions-to-buy-gsks-anthrax-treatment-raxibacumab-200717-5875921{/iframe}